Miraculins Completes Agreements with Diagnostic Technologies Ltd. and CIIRDF
Company to Receive $467,000 in Funding to Advance Risk Assessment Products for Preeclampsia
News & Media
Miraculins Announces Closing of $400,000 Private Placement Offering
Miraculins Inc. (TSX-V:MOM) (the “Company”), a company focused on developing and commercializing medical diagnostic tests for unmet clinical needs, has closed its previously announced private placement offering (the "Offering") with aggregate gross procee
Ray of Hope for Cancer Patients
The technology, called the AutoLITT System, uses an MRI-guided laser probe, passed through a hole in the skull about the size of a dime, to deliver laser interstitial thermal therapy (LITT) to heat and coagulate the tumour from the inside.
IH Systems Extends Global Reach into South Korean Medical Device Market
Medical device company, Intelligent Hospital Systems (IH Systems), has entered into an agreement with the South Korean pharmacy application specialists, Daeiltech (www.daeiltech.co.kr), based in Seoul. Daeiltech will provide direct sales and service suppo
Kane Biotech Announces Private Placement Offering
Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms (the “Company”), today announces a non-brokered private placement offering (the “Offering”) for gross proceeds of up
Scientists Learning To Target Bacteria Where They Live
In the arms race between humans and bacteria, the ability to form "biofilms" -- large aggregations of microbes embedded in a slimy matrix -- has been one of the weapons the organisms use to defeat the immune system, antibiotic drugs and other threats. But
MGI Pharma vet takes DiaMedica reins
Reggie Bowerman saw the doors close at MGI Pharma Inc.’s former headquarters late last year. Now, he’s aiming to open some new doors in biotech for a Canadian startup setting up shop in Minnesota.
Australia’s Leading Oncology Drug Compounder Chooses RIVA System
Pharmatel Fresenius Kabi Pty Ltd, an innovative Australian pharmaceutical company, has chosen the RIVA System (Robotic IV Automation)-a self-contained unit for filling IV syringes and bags- from Intelligent Hospital Systems (IH Systems) to consolidate its
Miraculins Announces Improved Detection of Aggressive Prostate Cancer With Combination of PSP94 and Free Over Total PSA Ratio
Discovery Compliments New Approaches to Prostate Cancer Treatment
Kane Biotech Receives an Additional Contribution from NRC-IRAP to Develop its DispersinB® Antibiofilm Wound Gel Product
Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce that the National Research Council Industrial Research Assistance Program (NRC-IRAP) has inc
Miraculins’ Completed P2V™ Immunoassay Confirms Mass Spectrometry Results
Company concludes research on prostate program and seeks licensing partner
Miraculins Announces Amendment to Private Placement Offering
Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, announces today an amendment to the terms of its private placement offering (the "Offering") announced on Novemb
LSAM Recognizes Leaders in the Life Science Sector
The Life Science Association of Manitoba (LSAM) awarded its annual Life Science Awards this week. Recognizing the leaders and innovators of the life science community, the awards highlight the great work being done in this growing and dynamic industry.
Genesys Venture Inc. Congratulates DiaMedica Inc., Kane Biotech Inc. and Sanomune Inc.
Genesys Venture Inc. (GVI), a life sciences management services firm, is pleased to congratulate DiaMedica Inc. (TSXV:DMA), Kane Biotech Inc. (TSXV:KNE) and Sanomune Inc. on being selected as winners in Canada’s Top 10 Life Sciences Competition, organized
DispersinB® Topical Wound Gel Passes First Set of Biocompatibility Tests
Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that DispersinB® Topical Wound Gel has passed the FDA-recommended Cytotoxicity and Primary Skin
Medicure Launches New Clinical Program
Medicure Inc. (TSX: MPH) is pleased to announce initiation of a clinical program to investigate the efficacy and safety of Avastrem(TM) (pyridoxal 5'- phosphate) for the management of tardive dyskinesia. The Company will provide details of the planned tar